TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2720577
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MS Contin tablet
Study: 2720577
Drug: Three 30
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 30 mg MS Contin tablets
Study: 31154571
Drug: 30-mg zinc
Normalized name: zinc citrate 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-mg zinc gluconate for 12 weeks
Study: 25968598
Drug: Sulforaphane (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulforaphane (60 mg daily for 6 months)
Study: 19085178
Drug: Trans-dermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trans-dermal fentanyl (TDF) patch (Group F, n=25)
Study: 19085178
Drug: Sustained-release oral
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oral morphine (SRM) (Group M, n=25)
Study: 19085178
Drug: Trans-dermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trans-dermal fentanyl (TDF) patch (Group F)
Study: 19085178
Drug: Sustained-release oral
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release oral morphine (SRM) (Group M)
Study: 29659193
Drug: Orlistat 27-mg
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat 27-mg chewable tablet
Study: 30021690
Drug: Orlistat 60-mg
Normalized name: orlistat 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 60-mg capsule
Study: 29659193
Drug: Orlistat 120-mg
Normalized name: orlistat 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orlistat 120-mg capsules (2 60-mg capsules)
Study: 24073873
Drug: FOS (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOS (4 g × 2 times/d)
Study: 19965647
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) added to daunorubicin/Ara-C/thioguanine chemotherapy
Study: 19965647
Drug: Daunorubicin/Ara-C/thioguanine chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin/Ara-C/thioguanine chemotherapy without ATRA
Study: 6403101
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for one year (premenoausal)
Study: 6403101
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for one year (postmenopausal)
Study: 6403101
Drug: No systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No systemic treatment (controls, postmenopausal)
Study: 26496418
Drug: Tear SIgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tear SIgA secretion rate <5.5 μg·min(‐1)
Study: 26496418
Drug: Tear SIgA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tear SIgA secretion rate >5.5 μg·min(‐1) or no decrease of >30%
Study: 18039020
Drug: 2% sertaconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% sertaconazole solution
Study: 18039020
Drug: 2% sertaconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% sertaconazole cream
Study: 12496749
Drug: Gemfibrozil 600
Normalized name: gemfibrozil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 600 mg twice daily for 3 days
Study: 9794174
Drug: Lowest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest quartile of exposure to organochlorine compounds
Study: 8775841
Drug: Pharmacologic treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatments for drug dependence
Study: 2198314
Drug: Four-drug regimen
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug regimen of rifampin, isoniazid, dapsone, and clofazimine for the first 3 months and clofazimine plus dapsone for the next 57 months
Study: 2198314
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen of dapsone plus clofazimine for 60 months
Study: 654409
Drug: Orciprenalin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orciprenalin (0.1 mg/kg bodyweight)
Study: 654409
Drug: Dopamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine (0.5 mg)
Study: 30536117
Drug: Intracervical Foley
Normalized name: eladocagene exuparvovec
DrugBank: Eladocagene exuparvovec (DB16780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracervical Foley balloon catheter insertion adjunct to intravaginal PgE2 insert (n = 146)
Study: 21472103
Drug: Diosmin 500
Normalized name: diosmin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmin 500 mg for 1 week
Study: 11210397
Drug: Naratriptan 2.5
Normalized name: naratriptan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naratriptan 2.5 mg tablet
Study: 8185742
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine i.v.
Study: 8185742
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg famotidine i.v. + 10 mg metoclopramide i.v.
Study: 8185742
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.3 M sodium citrate p.o.
Study: 8185742
Drug: 20 ml
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 ml 0.3 M sodium citrate p.o. + 10 mg metoclopramide i.v.
Study: 28488912
Drug: Tamoxifen or
Normalized name: tamoxifen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen or letrozole treatment
Study: 16439507
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (n = 15)
Study: 9133992
Drug: Protamine reversal
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protamine reversal of heparin
Study: 9133992
Drug: No reversal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No reversal of heparin
Study: 26600636
Drug: Topical flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical flurbiprofen 0.03%
Study: 2844340
Drug: CMV hyperimmune
Normalized name: CMV-immune globulin
DrugBank: Human cytomegalovirus immune globulin (DB13886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMV hyperimmune plasma (200 mg/kg body weight, given on four occasions during 2 days from day 3 to day 76 after transplantation)
Study: 27642131
Drug: Single-dose antihelminthic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose antihelminthic treatment (albendazole)
Study: 20089082
Drug: Tandospirone citrate
Normalized name: Tandospirone
DrugBank: Tandospirone (DB12833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tandospirone citrate (TC) 30 mg/day for 4 weeks
Study: 18759315
Drug: Exercise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise treatment (specialized hands-on exercise training with muscle strengthening)
Study: 8040776
Drug: Vancomycin added
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin added to parenteral alimentation solution (25 micrograms per milliliter)
Study: 2567667
Drug: Beta-blockers (propranolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (propranolol, metoprolol, oxprenolol)
Study: 1116100
Drug: megavoltage radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: megavoltage radiotherapy limited to involved lymph node sites followed by combination chemotherapy (MOPP)
Study: 25692792
Drug: Zagreb regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zagreb regimen (4 doses/3 visits) of purified chick embryo cell vaccine (PCECV)
Study: 25692792
Drug: Essen regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essen regimen (5 doses over 5 days) of purified chick embryo cell vaccine (PCECV)
Study: 15106887
Drug: Systemic‐behavioral-family therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic‐behavioral-family therapy (SBFT)
Study: 15106887
Drug: Non‐directive‐supportive therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non‐directive‐supportive therapy (NST)
Study: 10837944
Drug: Long-term hormonal
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term hormonal therapy
Study: 25793707
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg sodium valproate
Study: 9024957
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg sodium valproate
Study: 29736609
Drug: Standard prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylaxis (ciprofloxacin 500 mg B.I.D for 3 days)
Study: 29736609
Drug: Augmented prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented prophylaxis (ciprofloxacin + single preprocedure shot of 160 mg gentamicin IM)
Study: 29736609
Drug: Targeted prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted prophylaxis (rectal swab culture-based)
Study: 25162447
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of Sertraline, Mianserin, psycho-education, and Trauma-Focused Cognitive Behavioral Therapy (TFCBT)
Study: 25162447
Drug: Medication (antidepressants)
Normalized name: Medicated Shampoo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (antidepressants)
Study: 20724806
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet treatment initiation within 24 hours (early group)
Study: 20724806
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet treatment initiation more than 24 hours (late group)
Study: 11482924
Drug: Sotalol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (80 mg b.i.d.)
Study: 10921700
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no beta-blockade or antiarrhythmic drugs)
Study: 1389826
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion during surgery
Study: 1389826
Drug: Methohexitone infusion
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone infusion during surgery
Study: 1389826
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion in ICU
Study: 1389826
Drug: Methohexitone infusion
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone infusion in ICU
Study: 31319970
Drug: Lanreotide 120
Normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 120 mg subcutaneously every 28 days, up to 1 year or progression
Study: 26955809
Drug: Preoperative radiochemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative radiochemotherapy (15 fractions of 2.4 Gy combined with gemcitabine 1,000 mg/m² on days 1, 8, and 15)
Study: 26955809
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant chemotherapy after resection (four cycles in arm B)
Study: 26955809
Drug: Standard adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard adjuvant chemotherapy after resection (six cycles in arm A)
Study: 23146809
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard drug therapy, medical basic nursing, and conventional nursing)
Study: 12174789
Drug: Normal-dose ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal-dose ivermectin treatment
Study: 12174789
Drug: High-dose ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ivermectin treatment
Study: 12174789
Drug: Annual ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Annual ivermectin treatment
Study: 12174789
Drug: 3-monthly ivermectin
Normalized name: ivermectin 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-monthly ivermectin treatment
Study: 10442366
Drug: UFT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT plus calcium folinate administered three times per day for 21 days in combination with paclitaxel
Study: 2150907
Drug: Trospectomycin sulfate
Normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trospectomycin sulfate (U‐63,366F) 1,000 mg
Study: 508127
Drug: Amitriptyline (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline (up to four 25-mg tablets per day)
Study: 31004521
Drug: Cognitive Therapy/Borkovec's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Therapy/Borkovec's treatment package
Study: 31004521
Drug: Rational Emotive
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational Emotive Behavior Therapy
Study: 31004521
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy/Acceptance‐based behavioral therapy
Study: 24966147
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion group (levobupivacaine 0.25% at 5 ml/h)
Study: 24966147
Drug: ANT with
Normalized name: ADC Infant with Fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANT with continuous infusion
Study: 24966147
Drug: POST with
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: POST with continuous infusion
Study: 21900585
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) 50,000 IU intravenous bolus prior to PPCI and another bolus 24 hours later (n=26)
Study: 18954400
Drug: Ultrasound and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound and topical anesthetic
Study: 10634454
Drug: Donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil hydrochloride therapy, 5 mg/d for 6 weeks
Study: 8957200
Drug: Multifactorial treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial treatment programme (non-pharmacological treatment with possible drug therapy)
Study: 25728739
Drug: Gradual tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual tapering of desmopressin (ODM) - Group B: 240 μg ODM per day → 120 μg ODM per day → 120 μg ODM per alternate day → cessation
Study: 25728739
Drug: Gradual tapering
Normalized name: mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gradual tapering of desmopressin (ODM) - Group C: 240 μg ODM per day → 120 μg ODM per day → 60 μg ODM per day → 60 μg ODM per alternate day → cessation
Study: 17354095
Drug: Ultrasonic scaling
Normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasonic scaling + subgingival irrigation with sterile saline solution for 5 min/tooth
Study: 17354095
Drug: Subgingival irrigation
Normalized name: DOXYCYCLINE 10% SA SUBGINGIVAL SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subgingival irrigation with sterile saline solution for 5 min/tooth
Study: 15238098
Drug: New topical
Approvals — FDA: no, EMA: no, PMDA: no
Description: New topical formulation (0.25% alpha-glucosylrutin, 1% tocopheryl acetate, SPF 15 sunscreen)
Study: 15238098
Drug: Sunscreen-only gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen-only gel
Study: 9036799
Drug: Total number
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total number of units of blood products administered during transplantation
Study: 7932425
Drug: Nabumetone, 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nabumetone, 1000 mg nightly
Study: 3278942
Drug: 1-g 5-aminosalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g 5-aminosalicylic acid enemas
Study: 3278942
Drug: 1-g 5-aminosalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-g 5-aminosalicylic acid enemas (second trial)
Study: 23766412
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg ramosetron combined with 75 µg/kg midazolam (Group RM)
Study: 23766412
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg ramosetron (Group R)
Study: 23766412
Drug: 75 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 µg/kg midazolam (Group M)
Study: 18504090
Drug: Double-dose immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose immediate-release morphine (DD)
Study: 18504090
Drug: Single-dose immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose immediate-release morphine (SD)
Study: 16388973
Drug: Spinal cord
Normalized name: BOS TAURUS SPINAL CORD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal cord stimulation (SCS) in addition to best medical treatment
Study: 3070611
Drug: i.v. naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. naloxone (20 mg, 40 mg)
Study: 28985265
Drug: Invasive strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive strategy (n = 229) involving early coronary angiography, with immediate evaluation for percutaneous coronary intervention, coronary artery bypass graft, optimal medical therapy.
Study: 26690634
Drug: Alcohol prime
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol prime (0.6 g of alcohol per kg of body weight)
Study: 25910919
Drug: AS03-adjuvanted H5N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03-adjuvanted H5N1 vaccine (3.75μg of hemagglutinin antigen, two doses given 21 days apart)
Study: 25910919
Drug: TIV (licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIV (licensed seasonal inactivated trivalent influenza vaccine)
Study: 23994934
Drug: Actovegin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actovegin (5 ml, 200 mg daily for 4 weeks)
Study: 15782622
Drug: EVR after
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVR after more than 4 weeks of therapy
Study: 12701935
Drug: Higher daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher daily doses of inhaled corticosteroids (iCSTs) (>= 400 microg)
Study: 10214535
Drug: dexfenfluramine 15
Normalized name: dexfenfluramine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: dexfenfluramine 15 mg
Study: 8529780
Drug: Doxycycline 200
Normalized name: doxycycline 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline 200 mg on day 1 followed by 100 mg daily or 200 mg daily
Study: 8529780
Drug: Co-amoxiclav 500
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-amoxiclav 500 mg three times daily
Study: 8529780
Drug: Crossed over
Normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crossed over to alternative antibiotic
Study: 220656
Drug: ACTH 4-10
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACTH 4-10 (30 mg, s.c.)
Study: 27562137
Drug: Conventional salvage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional salvage chemotherapy
Study: 26591359
Drug: Xinfeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng Capsule (XC), three pills each time, three times daily for two therapeutic courses (one month each).
Study: 26591359
Drug: Methotrexate Tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate Tablet, four tablets each time, once per week for two therapeutic courses (one month each).
Study: 26591359
Drug: Xinfeng Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfeng Capsule (XC) vs Methotrexate Tablet after treatment.
Study: 16261956
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (1 mg/dose)
Study: 10327029
Drug: Epirubicin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 100 mg/m2 plus cisplatin 75 mg/m2 q 4 weeks
Study: 10327029
Drug: Cyclophosphamide 500
Normalized name: cyclophosphamide 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 500 mg/m2 plus epirubicin 75 mg/m2 plus cisplatin 50 mg/m2 q 4 weeks
Study: 1827613
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of etodolac twice daily
Study: 1827613
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of naproxen twice daily
Study: 28672273
Drug: Parent-administered early
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-administered early intervention program
Study: 17285571
Drug: Various treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various treatments for GERD
Study: 17285571
Drug: Models for
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Models for absolute treatment effects
Study: 15132728
Drug: Tibolone (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tibolone (2.5 mg once daily)
Study: 15132728
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate (2 mg daily) and dydrogesterone (20 mg daily for 2 weeks every 3 months)
Study: 31178152
Drug: 6-month trastuzumab
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month trastuzumab treatment (loading dose of 8 mg/kg followed by maintenance doses of 6 mg/kg)
Study: 31178152
Drug: 12-month trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 12-month trastuzumab treatment (loading dose of 8 mg/kg followed by maintenance doses of 6 mg/kg)
Study: 27059176
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behaviour therapy (ICBT)
Study: 22608115
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control condition (CC)